Literature DB >> 23607629

Aberrant expression of microRNAs in T cells from patients with ankylosing spondylitis contributes to the immunopathogenesis.

N-S Lai1, H-C Yu, H-C Chen, C-L Yu, H-B Huang, M-C Lu.   

Abstract

Ankylosing spondylitis (AS) is a chronic inflammatory disorder characterized by dysregulated T cells. We hypothesized that the aberrant expression of microRNAs (miRNAs) in AS T cells involved in the pathogenesis of AS. The expression profile of 270 miRNAs in T cells from five AS patients and five healthy controls were analysed by real-time polymerase chain reaction (PCR). Thirteen miRNAs were found potentially differential expression. After validation, we confirmed that miR-16, miR-221 and let-7i were over-expressed in AS T cells and the expression of miR-221 and let-7i were correlated positively with the Bath Ankylosing Spondylitis Radiology Index (BASRI) of lumbar spine in AS patients. The protein molecules regulated by miR-16, miR-221 and let-7i were measured by Western blotting. We found that the protein levels of Toll-like receptor-4 (TLR-4), a target of let-7i, in T cells from AS patients were decreased. In addition, the mRNA expression of interferon (IFN)-γ was elevated in AS T cells. Lipopolysaccharide (LPS), a TLR-4 agonist, inhibited IFN-γ secretion by anti-CD3(+) anti-CD28 antibodies-stimulated normal T cells but not AS T cells. In the transfection studies, we found the increased expression of let-7i enhanced IFN-γ production by anti-CD3(+) anti-CD28(+) lipopolysaccharide (LPS)-stimulated normal T cells. In contrast, the decreased expression of let-7i suppressed IFN-γ production by anti-CD3(+) anti-CD28(+) LPS-stimulated AS T cells. In conclusion, we found that miR-16, miR-221 and let-7i were over-expressed in AS T cells, but only miR-221 and let-7i were associated with BASRI of lumbar spine. In the functional studies, the increased let-7i expression facilitated the T helper type 1 (IFN-γ) immune response in T cells.
© 2013 British Society for Immunology.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23607629      PMCID: PMC3694534          DOI: 10.1111/cei.12089

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  57 in total

1.  Ten-year follow-up study of patients with Yersinia arthritis.

Authors:  M Leirisalo-Repo; H Suoranta
Journal:  Arthritis Rheum       Date:  1988-04

2.  Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria.

Authors:  S van der Linden; H A Valkenburg; A Cats
Journal:  Arthritis Rheum       Date:  1984-04

3.  The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis.

Authors:  F C Arnett; S M Edworthy; D A Bloch; D J McShane; J F Fries; N S Cooper; L A Healey; S R Kaplan; M H Liang; H S Luthra
Journal:  Arthritis Rheum       Date:  1988-03

4.  Quantitative analyses of sacroiliac biopsies in spondyloarthropathies: T cells and macrophages predominate in early and active sacroiliitis- cellularity correlates with the degree of enhancement detected by magnetic resonance imaging.

Authors:  M Bollow; T Fischer; H Reisshauer; M Backhaus; J Sieper; B Hamm; J Braun
Journal:  Ann Rheum Dis       Date:  2000-02       Impact factor: 19.103

5.  The recognition of HLA-B27 by human CD4(+) T lymphocytes.

Authors:  L H Boyle; J C Goodall; S S Opat; J S Gaston
Journal:  J Immunol       Date:  2001-09-01       Impact factor: 5.422

6.  Exacerbation of B27 positive spondyloarthropathy by enteric infections.

Authors:  R I Rynes; P S Volastro; L E Bartholomew
Journal:  J Rheumatol       Date:  1984-02       Impact factor: 4.666

7.  Relationship between disease activity and infection in patients with spondyloarthropathies.

Authors:  A Martínez; C Pacheco-Tena; J Vázquez-Mellado; R Burgos-Vargas
Journal:  Ann Rheum Dis       Date:  2004-10       Impact factor: 19.103

8.  HLA-B27-restricted T cells from patients with ankylosing spondylitis recognize peptides from B*2705 that are similar to bacteria-derived peptides.

Authors:  E Frauendorf; H von Goessel; E May; E Märker-Hermann
Journal:  Clin Exp Immunol       Date:  2003-11       Impact factor: 4.330

9.  Between adaptive and innate immunity: TLR4-mediated perforin production by CD28null T-helper cells in ankylosing spondylitis.

Authors:  Bernd Raffeiner; Christian Dejaco; Christina Duftner; Werner Kullich; Christian Goldberger; Sandra C Vega; Michael Keller; Beatrix Grubeck-Loebenstein; Michael Schirmer
Journal:  Arthritis Res Ther       Date:  2005-10-18       Impact factor: 5.156

10.  Salmonella reactive arthritis in established ankylosing spondylitis.

Authors:  I R Paul; E S Mitchell; A L Bell
Journal:  Ulster Med J       Date:  1988-10
View more
  35 in total

1.  Evaluation of DNMT1 gene expression profile and methylation of its promoter region in patients with ankylosing spondylitis.

Authors:  Saeed Aslani; Mahdi Mahmoudi; Masoud Garshasbi; Ahmad Reza Jamshidi; Jafar Karami; Mohammad Hossein Nicknam
Journal:  Clin Rheumatol       Date:  2016-09-16       Impact factor: 2.980

Review 2.  Epigenetics of osteoarticular diseases: recent developments.

Authors:  S B Roberts; E Wootton; L De Ferrari; O M Albagha; D M Salter
Journal:  Rheumatol Int       Date:  2015-03-27       Impact factor: 2.631

3.  MicroRNA values in children with rheumatic carditis: a preliminary study.

Authors:  Gokhan Gumus; Dilek Giray; Onur Bobusoglu; Lulufer Tamer; Derya Karpuz; Olgu Hallioglu
Journal:  Rheumatol Int       Date:  2018-05-29       Impact factor: 2.631

4.  Increased HDAC3 and decreased miRNA-130a expression in PBMCs through recruitment HDAC3 in patients with spinal cord injuries.

Authors:  Yu-Dong Ma; Jing Fang; Hong Liu; Li Zhou
Journal:  Int J Clin Exp Pathol       Date:  2015-02-01

Review 5.  Genomics and epigenomics in rheumatic diseases: what do they provide in terms of diagnosis and disease management?

Authors:  Patricia Castro-Santos; Roberto Díaz-Peña
Journal:  Clin Rheumatol       Date:  2017-07-20       Impact factor: 2.980

Review 6.  Activation of mTOR (mechanistic target of rapamycin) in rheumatic diseases.

Authors:  Andras Perl
Journal:  Nat Rev Rheumatol       Date:  2015-12-24       Impact factor: 20.543

7.  Diagnostic accuracy of miRNAs as potential biomarkers for systemic lupus erythematosus: a meta-analysis.

Authors:  Zi-Wei Dai; Hong Wang; Wen-Juan Xu; Zhi-Hui Wang; Sheng-Qian Xu; Bin Wang; Dong-Qing Ye
Journal:  Clin Rheumatol       Date:  2018-07-06       Impact factor: 2.980

8.  miR-573 is a negative regulator in the pathogenesis of rheumatoid arthritis.

Authors:  Lin Wang; Guanhua Song; Yabing Zheng; Dan Wang; Hongyan Dong; Jihong Pan; Xiaotian Chang
Journal:  Cell Mol Immunol       Date:  2015-07-13       Impact factor: 11.530

9.  Plasma let-7i, miR-16, and miR-221 levels as candidate biomarkers for the assessment of ankylosing spondylitis in Mexican patients naïve to anti-TNF therapy.

Authors:  Paola Reyes-Loyola; Pedro Rodríguez-Henríquez; Martha A Ballinas-Verdugo; Luis M Amezcua-Castillo; Yaneli Juárez-Vicuña; Valentín Jiménez-Rojas; Ricardo Márquez-Velasco; Fausto Sánchez-Muñoz; Luis M Amezcua-Guerra
Journal:  Clin Rheumatol       Date:  2019-03-25       Impact factor: 2.980

10.  Increased miR-223 expression in T cells from patients with rheumatoid arthritis leads to decreased insulin-like growth factor-1-mediated interleukin-10 production.

Authors:  M-C Lu; C-L Yu; H-C Chen; H-C Yu; H-B Huang; N-S Lai
Journal:  Clin Exp Immunol       Date:  2014-09       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.